• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用于治疗非结核分枝杆菌病的新型抗生物膜策略。

New antibiofilm strategies for the management of nontuberculous mycobacteria diseases.

机构信息

Department of Clinical Microbiology, IIS-Fundación Jiménez Díaz, UAM, Madrid, Spain.

CIBERINFEC-CIBER de Enfermedades Infecciosas, Madrid, Spain.

出版信息

Expert Opin Pharmacother. 2024 Oct;25(15):2035-2046. doi: 10.1080/14656566.2024.2412250. Epub 2024 Oct 9.

DOI:10.1080/14656566.2024.2412250
PMID:39365052
Abstract

INTRODUCTION

Nontuberculous mycobacteria (NTM) represent a group of microorganisms comprising more than 190 species. NTM infections have increased recently, and their treatment is a major challenge because to their resistance to conventional treatments. This review focuses on innovative strategies aimed at eradicating NTM biofilms, a critical factor in their resistance. Important areas addressed include biofilm formation mechanisms, current therapeutic challenges, and novel treatment approaches. The main objective is to compile and analyze information on these emerging strategies, identifying pivotal research directions and recent advancements.

AREAS COVERED

A review of the scientific literature was conducted to identify emerging novel therapies for the treatment of NTM infections and to explore potential synergies with existing treatments.

EXPERT OPINION

Experts highlights a limited understanding of optimal treatment regimens, often supported by insufficient scientific evidence. Current therapies are typically prolonged, involve multiple antibiotics with adverse effects, and frequently do not achieve patient cure. Certain species are even considered virtually impossible to eradicate. A thorough understanding of these new approaches is imperative for improving patients outcomes. This review provides a robust foundation for developing of more effective antibacterial strategies, which are essential because of the increasing incidence of NTM infections and the limitations of existing therapies.

摘要

简介

非结核分枝杆菌(NTM)是一组包含超过 190 种微生物的菌群。NTM 感染最近有所增加,由于它们对常规治疗的耐药性,其治疗是一个主要挑战。本综述重点关注旨在根除 NTM 生物膜的创新策略,这是其耐药性的一个关键因素。讨论的重要领域包括生物膜形成机制、当前治疗挑战和新的治疗方法。主要目标是综合和分析有关这些新兴策略的信息,确定关键的研究方向和最新进展。

涵盖领域

对科学文献进行了回顾,以确定用于治疗 NTM 感染的新兴新型疗法,并探讨与现有疗法的潜在协同作用。

专家意见

专家强调,人们对最佳治疗方案的理解有限,通常缺乏充分的科学证据。目前的治疗通常是长期的,涉及多种具有副作用的抗生素,并且经常无法治愈患者。某些物种甚至被认为几乎不可能根除。彻底了解这些新方法对于改善患者的预后至关重要。本综述为制定更有效的抗菌策略提供了坚实的基础,鉴于 NTM 感染的发生率不断增加和现有疗法的局限性,这些策略是必要的。

相似文献

1
New antibiofilm strategies for the management of nontuberculous mycobacteria diseases.用于治疗非结核分枝杆菌病的新型抗生物膜策略。
Expert Opin Pharmacother. 2024 Oct;25(15):2035-2046. doi: 10.1080/14656566.2024.2412250. Epub 2024 Oct 9.
2
Managing antibiotic resistance in nontuberculous mycobacterial pulmonary disease: challenges and new approaches.非结核分枝杆菌性肺病中抗生素耐药的管理:挑战与新方法。
Expert Rev Respir Med. 2019 Sep;13(9):851-861. doi: 10.1080/17476348.2019.1638765. Epub 2019 Jul 8.
3
Medications and monitoring in nontuberculous mycobacteria infections.非结核分枝杆菌感染的药物治疗与监测。
Clin Chest Med. 2015 Mar;36(1):55-66. doi: 10.1016/j.ccm.2014.11.001. Epub 2014 Dec 18.
4
State-of-the-art treatment strategies for nontuberculous mycobacteria infections.非结核分枝杆菌感染的最新治疗策略。
Expert Opin Pharmacother. 2020 Jun;21(8):969-981. doi: 10.1080/14656566.2020.1740205. Epub 2020 Mar 21.
5
Resistance mechanisms and drug susceptibility testing of nontuberculous mycobacteria.非结核分枝杆菌的耐药机制与药敏试验。
Drug Resist Updat. 2012 Jun;15(3):149-61. doi: 10.1016/j.drup.2012.04.001. Epub 2012 Apr 21.
6
Treatment of slowly growing mycobacteria.缓慢生长分枝杆菌的治疗。
Clin Chest Med. 2015 Mar;36(1):79-90. doi: 10.1016/j.ccm.2014.10.005. Epub 2014 Nov 6.
7
Antimycobacterial Susceptibility Testing of Nontuberculous Mycobacteria.非结核分枝杆菌的抗分枝杆菌药物敏感性测试。
J Clin Microbiol. 2019 Sep 24;57(10). doi: 10.1128/JCM.00834-19. Print 2019 Oct.
8
Shifting paradigms of nontuberculous mycobacteria in cystic fibrosis.囊性纤维化中非结核分枝杆菌的范式转变。
Respir Res. 2014 Apr 11;15(1):41. doi: 10.1186/1465-9921-15-41.
9
Recent advances in molecular diagnostics and understanding mechanisms of drug resistance in nontuberculous mycobacterial diseases.近年来,在非结核分枝杆菌病的分子诊断学和耐药机制方面取得了进展。
Infect Genet Evol. 2019 Aug;72:169-182. doi: 10.1016/j.meegid.2018.10.003. Epub 2018 Oct 11.
10
Cutaneous nontuberculous mycobacteria infections: A retrospective case series of 78 patients from the Texas Gulf Coast region.皮肤非结核分枝杆菌感染:德克萨斯海湾地区 78 例患者的回顾性病例系列。
J Am Acad Dermatol. 2019 Sep;81(3):730-739. doi: 10.1016/j.jaad.2019.04.022. Epub 2019 Apr 16.